| Title: |
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial |
| Authors: |
Moyle, Graeme, Assoumou, Lambert, de Castro, Nathalie, Post, Frank A, Curran, Adrian, Rusconi, Stefano, De Wit, Stephane, Stephan, Christoph, Raffi, François, Johnson, Margaret, Masia, Mar, Vera, Jaime, Jones, Bryn, Grove, Richard, Fletcher, Carl, Duffy, Annie, Morris, Kellie, Pozniak, Anton, Moyle, Graeme, de Castro, Nathalie, Post, Frank, Curran, Adrian, Rusconi, Stefano, De Wit, Stephane, Stephan, Christoph, Raffi, François, Johnson, Margaret, Masia, Mar, Vera, Jaime, Winston, Alan, Kegg, Stephen, Waters, Laura, Orkin, Chole, Ustianowski, Andrew, Reeves, Iain, Leen, Clifford, Perry, Meghan, Portilla, Joaquin, Blanco, Jose Luis, Montejaro, Rocio, Domingo, Pere, Molina, Jean Michel, Katlama, Christine, Morlat, Philippe, Kenyon, Christopher, Puoti, Massimo, Rizzardini, Giuliano, Castagna, Antonella, Castelli, Francesco, Giacomelli, Andrea, Rockstroh, Jürgen, Esser, Stefan, Hoffmann, Christian, Mallon, Patrick |
| Source: |
The Lancet HIV; March 2024, Vol. 11 Issue: 3 pe156-e166, 11p |
| Abstract: |
The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations whose HIV was previously managed with other treatment regimens. |
| Database: |
Supplemental Index |
